These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report. De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518 [TBL] [Abstract][Full Text] [Related]
5. Three cases of Anti-MDA5 positive dermatomyositis with interstitial lung disease and pneumomediastium. Figueiredo C; Matos AL; Calvao J; Goncalo M Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762870 [No Abstract] [Full Text] [Related]
6. Cutaneous Ulcerations in Anti-MDA5 Dermatomyositis. Charrow A; Vleugels RA N Engl J Med; 2019 Aug; 381(5):465. PubMed ID: 31365803 [No Abstract] [Full Text] [Related]
7. Assessing Time of Onset for Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Dermatomyositis. Lin RR; Warp PV; Maderal AD; Elman SA JAMA Dermatol; 2024 May; 160(5):575-577. PubMed ID: 38598206 [TBL] [Abstract][Full Text] [Related]
8. [Dermatomyositis associated with anti-MDA5 antibodies and pneumocystis pneumonia: Two lethal cases]. Aymonier M; Abed S; Boyé T; Barazzutti H; Fournier B; Morand JJ Ann Dermatol Venereol; 2017 Apr; 144(4):279-283. PubMed ID: 27839728 [TBL] [Abstract][Full Text] [Related]
9. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. Kurtzman DJB; Vleugels RA J Am Acad Dermatol; 2018 Apr; 78(4):776-785. PubMed ID: 29229575 [TBL] [Abstract][Full Text] [Related]
10. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008 [TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease. Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718 [TBL] [Abstract][Full Text] [Related]
12. Eyelid edema as first manifestation of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease: A case report. Ludriksone L; Pfeil A; Schliemann S; Elsner P J Dtsch Dermatol Ges; 2020 Mar; 18(3):263-265. PubMed ID: 31922645 [No Abstract] [Full Text] [Related]
13. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis. Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789 [TBL] [Abstract][Full Text] [Related]
14. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis. Nandy A; Gaïni S; Sore P Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891 [No Abstract] [Full Text] [Related]
15. The clinical spectrum of dermatomyositis and the new autoantibodies - with regard to two clinical cases with distinct associations. Calvão da Silva JCM; Santiago L; Brites MM; Gonçalo M Australas J Dermatol; 2020 May; 61(2):e241-e243. PubMed ID: 31881093 [TBL] [Abstract][Full Text] [Related]